Viatris director Malik Rajiv sells over $3.5m in company stock By Investing.com

Viatris Inc (NASDAQ:) Director Malik Rajiv has recently sold a significant portion of his holdings in the pharmaceutical company, according to the latest filings. Rajiv disposed of a total of 350,960 shares in two separate transactions, amounting to over $3.5 million in value.

On June 13, 2024, Rajiv sold 85,660 shares at a weighted average price of $10.5153, with the price of shares ranging from $10.50 to $10.525. Following this transaction, he sold an additional 264,300 shares on June 14 at a weighted average price of $10.1789, with individual sales prices varying between $10.17 and $10.205. These sales resulted in a total of $3,591,023 in proceeds for the director.

After these transactions, Rajiv’s direct holdings in Viatris Inc have decreased significantly, although he still owns a substantial number of shares indirectly through an irrevocable trust. The latest report shows that the director has a direct ownership of 645,519 shares following the sales, and an additional 460,319 shares are held indirectly.

Investors often keep an eye on insider trading activities to gain insights into a company’s performance and the confidence level of its executives and directors. Large sales such as these can sometimes lead to speculation about the company’s future prospects or an insider’s view of its valuation.

Viatris Inc, a company known for its pharmaceutical preparations, has not commented on these transactions. The sales were conducted in a routine manner, and as per regulatory requirements, full details regarding the number of shares sold at each price within the stated ranges can be provided upon request.

The transactions were officially signed off by Kevin Macikowski, acting by power of attorney, on June 17, 2024.

In other recent news, Viatris Inc. has reported strong financial results for the first quarter of 2024, with total revenue reaching approximately $3.7 billion. The company’s adjusted EBITDA stood at about $1.2 billion, with an adjusted EPS of $0.67 per share, and free cash flow of approximately $565 million. Viatris confirmed that it is on track with its strategic initiatives, returning $393 million to shareholders via dividends and share repurchases in Q1.

Viatris also announced the appointment of Rogerio Vivaldi Coelho, M.D., to its Board of Directors. Dr. Vivaldi, an experienced leader in the biopharmaceutical industry, will serve on the Science and Technology Committee of the Board. His extensive background includes leadership roles at various biotech companies, most recently as President and CEO of Sigilon Therapeutics.

These are the latest developments in the company’s continuous efforts to enhance its innovative pipeline and strategic growth. Despite a 3% decline in its North America business, Viatris experienced growth in emerging markets and Europe, and expects new product revenue of $450 to $550 million. The company reaffirmed its 2024 financial guidance and anticipates stronger free cash flow in the second half of the year.

InvestingPro Insights

Amidst the news of Viatris Inc (NASDAQ:VTRS) Director Malik Rajiv’s recent stock sale, a deeper dive into the company’s financial health and market performance may offer investors a clearer picture. According to InvestingPro data, Viatris has a market capitalization of $12.06 billion, suggesting a solid presence in the pharmaceutical industry. Investors may also note the company’s P/E ratio, which stands at a forward-looking 9.47, indicating potential for investment value relative to earnings. Additionally, Viatris boasts a significant dividend yield of 4.72%, a figure that income-focused investors might find particularly appealing.

From the perspective of InvestingPro Tips, it’s interesting to observe that Viatris’s management has been actively repurchasing shares, a move that often signals confidence in the company’s future prospects and a commitment to increasing shareholder value. Furthermore, the company’s net income is expected to grow this year, a factor that could contribute to an optimistic outlook for prospective and current investors alike. With these considerations in mind, those interested in Viatris’s performance may find it worthwhile to explore the comprehensive list of InvestingPro Tips available at Investing.com. The platform offers an additional 9 tips, providing a more nuanced understanding of the company’s position.

To gain access to these insights and more, investors are encouraged to consider a subscription to InvestingPro. By using the coupon code PRONEWS24, readers can enjoy an additional 10% off a yearly or biyearly Pro and Pro+ subscription, enhancing their investment research with valuable data and expert analysis.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.